---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009813"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:55:12.352019+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised

## Summary
- Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.
- Net proceeds to fund development of NXP800 (Phase 1b ARID1a-mutated ovarian cancer) and NXP900 (Phase 1a SRC kinase inhibitor).
- Lucid Capital Markets sole book runner; offering closed February 6, 2025, after option exercise.

## SEC filing metadata
- accession: 0001104659-25-009813
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925009813/0001104659-25-009813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925009813/tm255441d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009813
- JSON: https://secwatch.observer/filing/0001104659-25-009813.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.